May 30, 2007
All aboard at Predictive Biosciences
By Cory Hopkins
Predictive Biosciences has formed a six-member Scientific Advisory Board as it attempts to develop diagnostic tools to address unmet clinical needs for cancer patients and survivors.
Lexington-based Predictive develops diagnostic products for cancer management, with a focus on cancer survivors. It is in the process of commercializing its portfolio of urinary protein biomarkers for cancer management, the company said.
The board will consist of co-founders Dr. Marsha Moses and Dr. Bruce Zetter, who will serve as chairman of the scientific advisory board; Dr. Martin Fleischer, chairman of the department of clinical laboratories and chief of clinical chemistry service at Memorial Sloan-Kettering Cancer Center in New York; Dr. Judah Folkman, director of the vascular biology program in the department of surgery at Children's Hospital in Boston; Dr. Kevin Loughlin, director of urologic research at Brigham and Women's Hospital in Boston; and Dr. John C. Reed, president and CEO of the Burnham Institute for Medical Research in La Jolla, Calif.
Lexington-based Predictive develops diagnostic products for cancer management, with a focus on cancer survivors. It is in the process of commercializing its portfolio of urinary protein biomarkers for cancer management, the company said.
The board will consist of co-founders Dr. Marsha Moses and Dr. Bruce Zetter, who will serve as chairman of the scientific advisory board; Dr. Martin Fleischer, chairman of the department of clinical laboratories and chief of clinical chemistry service at Memorial Sloan-Kettering Cancer Center in New York; Dr. Judah Folkman, director of the vascular biology program in the department of surgery at Children's Hospital in Boston; Dr. Kevin Loughlin, director of urologic research at Brigham and Women's Hospital in Boston; and Dr. John C. Reed, president and CEO of the Burnham Institute for Medical Research in La Jolla, Calif.
WBJ Web Partners
Most Recent
Most Recent
0 Comments